


# SCOPE 2

#TCT2020



AMERICAN  
COLLEGE of  
CARDIOLOGY

**Trial Description:** Patients with severe AS undergoing transfemoral TAVR were randomized in a 1:1 fashion to Acurate neo or CoreValve Evolut TAVR valves. They were followed for 1 year.



## RESULTS

- Primary endpoint (death/stroke): Acurate neo vs. CoreValve Evolut: 15.8% vs. 13.9% ( $p_{\text{noninferiority}} = 0.055$ )
- All-cause mortality: 13% vs. 9% ( $p = 0.13$ ), CV mortality: 8% vs. 4% ( $p = 0.01$ )
- New pacemaker implantation: 11% vs. 18% ( $p = 0.004$ ), 30-day paravalvular leak (PVL)  $\geq$  mild: 72.8% vs. 55.1% ( $p < 0.0001$ )

## CONCLUSIONS

- TAVR with Acurate neo valve did not meet criteria for noninferiority compared with CoreValve Evolut valve among patients undergoing transfemoral TAVR (both are self-expanding supra-annular porcine valves)
- Rates of permanent pacemaker were lower with Acurate neo, while PVL rates were higher; cardiac mortality was also higher
- Long-term outcomes are awaited